Lercanidipine-d3 (hydrochloride)

Lercanidipine-d3 (hydrochloride) is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB) . Lercanidipine has long lasting antihypertensive action and reno-protective effect[1][2][3].

Product Specifications

CAS Number

[1189954-18-4]

UNSPSC

12352005

Target

Calcium Channel; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

98.26

Solubility

DMSO : 20 mg/mL (ultrasonic; warming)

Smiles

C(OC(CN(CCC(C1=CC=CC=C1)C2=CC=CC=C2)C([2H])([2H])[2H])(C)C)(=O)C=3C(C(C(OC)=O)=C(C)NC3C)C4=CC(N(=O)=O)=CC=C4.Cl

Molecular Formula

C36H39D3ClN3O6

Molecular Weight

651.21

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60 (11) : p. 1364-70.|[3]Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5 (8) : p. 981-7.|[4]Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 2017;8 (4) :155-165.